Eli Lilly has agreed to acquire cancer drug developer Kelonia Therapeutics in a deal that could be worth up to $7 billion, according to reporting by CNBC on May 10. The transaction centers on Kelonia’s experimental technology to reprogram a patient’s own immune cells directly inside the body, a method known as in vivo CAR-T.
Lilly is positioning the acquisition as a way to expand its oncology pipeline with a newer form of cell-based cancer treatment that aims to be less complex than current approaches. Financial terms reported by CNBC indicate that the total value of the deal, if certain milestones are met, could reach the multi‑billion‑dollar range, though detailed payment structures were not disclosed.
What Lilly Is Buying
Kelonia is a cancer drug maker focused on a specific type of immunotherapy called CAR-T, short for chimeric antigen receptor T‑cell therapy. Traditional CAR-T treatments involve removing a patient’s T‑cells — a type of white blood cell that helps coordinate the immune response — engineering them in a laboratory to better recognize cancer cells, and then infusing them back into the patient.
According to CNBC’s account of the deal, Kelonia is developing an in vivo CAR-T platform. “In vivo” means “inside the living body.” Instead of taking T‑cells out and modifying them in a lab, Kelonia’s approach is designed to deliver genetic instructions directly into the patient so that T‑cells are reprogrammed while they remain in the bloodstream or tissues.
Lilly’s decision to acquire Kelonia suggests the larger company sees strategic value in this approach, which is still in development and has not yet become a standard treatment. The CNBC report identifies the in vivo CAR-T platform as the central scientific asset drawing Lilly to the deal.
How the Deal Is Structured
CNBC reports that the agreement between Eli Lilly and Kelonia could total up to $7 billion. That figure typically reflects a combination of an upfront payment and additional milestone-based payments that depend on research, regulatory, or commercial progress. The precise breakdown of upfront cash versus future contingent payments was not detailed in the available reporting.
Deals of this size in biotechnology often include:
- An initial payment when the transaction closes, giving the buyer control of the company or its assets.
- Development milestones, paid if drug candidates reach specific stages such as successful early-stage trials.
- Regulatory or sales milestones, tied to approvals or revenue targets.
While CNBC’s May 10 report confirms the overall potential value and Lilly’s plan to acquire Kelonia, it does not specify which of these components apply or how much of the $7 billion figure is guaranteed versus contingent.
Why In Vivo CAR-T Matters in Cancer Research
The in vivo CAR-T approach that Kelonia is pursuing aims to address some of the limitations of existing CAR-T therapies. Current CAR-T treatments, as described in medical literature, involve complex manufacturing: each patient’s cells must be collected, engineered individually, and then returned. This process can be time‑consuming and costly, and it requires specialized facilities.
By contrast, in vivo CAR-T technology, as summarized in the CNBC report on Kelonia, is intended to reprogram T‑cells directly in the patient. In principle, that could simplify logistics by:
- Reducing or eliminating the need to handle cells outside the body
- Potentially shortening the time from diagnosis to treatment
- Making it easier to treat more patients if manufacturing becomes more standardized
However, Kelonia’s work remains experimental. CNBC’s coverage indicates that Lilly is acquiring a company developing this technology, not a widely approved therapy already on the market. That means key questions about safety, effectiveness, and cost will need to be answered through clinical trials and regulatory review.
What Is Known and What Is Still Unclear
Based on CNBC’s May 10 reporting, several points are clear:
- Eli Lilly has agreed to acquire Kelonia, a cancer drug company.
- The deal’s potential value is up to $7 billion.
- Kelonia’s main technology focuses on in vivo CAR-T, reprogramming T‑cells inside the body to attack cancer.
Other important details are not yet fully described in the available public reporting:
- The exact size of any upfront payment Lilly will make at closing
- The specific milestones that could bring the total value to $7 billion
- The stage of development of Kelonia’s leading drug candidates
- The expected timeline for regulatory filings or clinical trial readouts
CNBC notes that independent corroboration of all aspects of the deal remains limited at this early stage. As with many biotech acquisitions announced through a single primary report, additional disclosures from the companies or regulatory filings would provide a more complete picture of the transaction terms and development plans.
What This Means for Patients and the Industry
For now, the immediate impact of Lilly’s move is on its own research portfolio and on Kelonia’s future as an independent company. The CNBC report frames the acquisition as a strategic bet on a next‑generation form of cell therapy, rather than a change to existing treatment options that patients can access today.
If Kelonia’s in vivo CAR-T approach proves safe and effective in clinical testing and wins regulatory approval in the coming years, it could add to the range of tools doctors use against certain cancers. That outcome, however, depends on scientific and regulatory steps that have not yet occurred and are not guaranteed.
From an industry perspective, Lilly’s willingness to commit up to $7 billion for an early‑stage technology signals continued interest among large pharmaceutical companies in advanced immunotherapies. The CNBC coverage underscores that major firms are prepared to invest heavily in platforms that promise to make complex treatments like CAR-T more scalable, even when those platforms are still under development.
What to Watch Next
The key developments to watch, based on the information currently available, include:
- Formal announcements or detailed statements from Eli Lilly and Kelonia outlining the structure of the deal
- Regulatory filings that could clarify financial terms and timelines
- Updates on the progress of Kelonia’s in vivo CAR-T programs, including any entry into or advancement of clinical trials
For now, Lilly’s planned acquisition of Kelonia marks a significant financial and strategic commitment to a developing cancer technology that aims to reprogram the immune system from within the body, with its ultimate impact dependent on results that still lie ahead.
